Zetta Genomics, a Cambridge, UK-based genomic data technology company, raised £1.9M in Second Seed funding.
The round was led by Nina Capital with participation from APEX Ventures and Cambridge Enterprise, the innovation arm of the University of Cambridge.
The company intends to use the funds to accelerate growth of its XetaBase platform and expand operations. Second round funding positions Zetta Genomics for growth as it approaches Series A funding in 2024 – to:
– encompass 500,000 genomes under management;
– configure customer success capabilities – to continue excellence in delivery while capturing and focusing on fast-evolving customer priorities;
– deepen bioinformatics and translation expertise;
– build out engineering capabilities to ensure a continuous cycle of innovation, development and delivery;
– Continue to grow internationally, with an initial focus on the UK, US and Spain.
Founded in 2017 and led by CEO Mark Bailey, Zetta Genomics is a genomic data technology company whose XetaBase genomic data management platform simplifies tertiary genomic data analysis aggregating, indexing and enriching secondary data at scale and speed – to accelerate discovery, diagnosis and the delivery of genomic medicine.
Zetta is a spin-out from the University of Cambridge and Genomics England. It has an international office in Valencia, Spain.
FinSMEs